Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC

Fig. 4

Clonal structure and phylogenetic reconstruction of PDXs in the acquired resistance group. a, d Clonal evolution in response to cetuximab treatment inferred from WES sequencing. Plots of clonal lineages and frequency changes over time and in response to cetuximab treatment for two cases (PDX_500 and PDX_549). b, e The cellular prevalence of mutation clusters across PDX samples identified by PyClone analysis. The founding clone is indicated in light red as subclone_0, with subsequent subclones shown in distinct colors. The line graphs show the clonal prevalence of each subclone in multiple samples from the same case (corresponding to the area of the phylogenetic trees). c, f Phylogenetic trees constructed based on the mutation clusters for PDX_500 (a) and PDX_549 (d) in the acquired resistance group. g Analysis of significantly differentially enriched pathways in newly generated subclones in the acquired resistance group. h The line graphs illustrate changes in the CCF value of gene mutations (TAGAP, PAK6, DLC1, RASAL3, PIK3R3) through cetuximab treatment in acquired resistance group

Back to article page